Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ALT - Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

ALT - Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Altimmune Inc.
  • Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH.
  • Although still in a very early phase of trials, CRV431 has presented very promising preclinical results.
  • The ALT reduction obtained in last phase IIa trial outperformed all competing drug candidate trials to date.
  • I consider that Hepion presents a very good investment opportunity at current price levels, with a view to 1 or 2 years.

For further details see:

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Stock Information
Company Name: Altimmune Inc.
Stock Symbol: ALT
Market: NASDAQ
Website: altimmune.com
Menu
ALT ALT Quote ALT Short ALT News ALT Articles ALT Message Board
Get ALT Alerts

News, Short Squeeze, Breakout and More Instantly...